- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05889741
Combinazione del blocco del ganglio stellato con esposizione prolungata per PTSD
Combinazione del blocco del ganglio stellato con esposizione prolungata per PTSD: uno studio clinico randomizzato
The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment.
The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.
Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Amanda Flores
- Numero di telefono: 210-562-6726
- Email: floresa13@uthscsa.edu
Luoghi di studio
-
-
Texas
-
Fort Hood, Texas, Stati Uniti, 76544
- Reclutamento
- Carl R. Darnall Army Medical Center
-
Contatto:
- Paul Fowler
- Numero di telefono: 726-225-5520
- Email: fowlerp@uthscsa.edu
-
Investigatore principale:
- Caleb Dickinson, DO
-
Fort Sam Houston, Texas, Stati Uniti, 78234
- Reclutamento
- Brook Army Medical Center (BAMC)
-
Contatto:
- Wilson B Pfeiffer, DO
- Numero di telefono: 210-916-8256
- Email: wilson.b.pfeiffer.mil@health.mil
-
Investigatore principale:
- Wilson B Pfeiffer, Do
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- University of Texas Health Science Center at San Antonio
-
Contatto:
- Amanda Flores
- Numero di telefono: 210-562-6726
- Email: floresa13@uthscsa.edu
-
Investigatore principale:
- Alan Peterson, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Active duty and retired military service members ages 18-65 years
- PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale
- Able to speak and read English (due to standardization of outcome measures)
- Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at a military treatment facility (MTF) where the stellate ganglion block will be placed.
Exclusion Criteria:
- Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index - Suicidality Subscale and the Self-Injurious Thoughts and Behaviors Interview short form) and corroborated by a clinical risk assessment by a credentialed provider.
- Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization (as determined by clinical judgment)
- Symptoms of moderate to severe substance use (to include alcohol) warranting immediate intervention based on clinical judgment.
- Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
- Pregnancy or breastfeeding
- Current anticoagulant use
- History of bleeding disorder
- Infection or mass at injection site
- Myocardial infarction within 6 months of procedure
- Pathologic bradycardia or irregularities of heart rate or rhythm
- Symptomatic hypotension
- Phrenic or laryngeal nerve palsy
- History of glaucoma
- Uncontrolled seizure disorder
- History of allergy to local anesthetics
- Current use of Class III antiarrhythmics
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Stellate Ganglion Block
One time administration of a stellate ganglion block |
6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
Altri nomi:
|
|
Comparatore placebo: Sham SGB
One time administration |
6.5cc of Normal Saline one time into the stellate ganglion. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)
Lasso di tempo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)
Lasso di tempo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 20-item self-report measure that assesses the presence and change in severity of PTSD symptoms using the Diagnostic and Statistical Manual of mental disorders (DSM-5). Total severity scores range from 0 to 80 with higher score indictive of greater PTSD severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patient Health Questionnaire-9 items (PHQ-9)
Lasso di tempo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of depressive symptoms. Total scores range from 0 to 27 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
General Anxiety Disorder Screener - 7 Items (GAD-7)
Lasso di tempo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of general anxiety symptoms. Total scores range from 0 to 21 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Posttraumatic Cognitions Inventory (PTCI)
Lasso di tempo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 36-item self-report measure that assesses change in self-blame, negative cognitions about self, and negative cognitions about the world following trauma exposure. Total scores range from 33 to 231 with higher scores reflective of more problematic cognitions. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Psychophysiological arousal - Galvanic Skin Response
Lasso di tempo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring galvanic skin response |
Two weeks
|
|
Psychophysiological arousal - Skin Temperature
Lasso di tempo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring skin temperature |
Two weeks
|
|
Psychophysiological arousal - Heart Rate
Lasso di tempo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring heart rate |
Two weeks
|
|
Psychophysiological arousal - Interbeat Interval
Lasso di tempo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring interbeat interval |
Two weeks
|
|
Psychophysiological arousal - Three-Dimensional Accelerometer Movement
Lasso di tempo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring three-dimensional accelerometer movement |
Two weeks
|
|
Psychophysiological arousal - Electrodermal Activity
Lasso di tempo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring electrodermal activity |
Two weeks
|
|
Psychophysiological arousal - Photoplethysmography
Lasso di tempo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring photoplethysmography |
Two weeks
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Alan Peterson, PhD, The University of Texas Health Science Center at San Antonio
Pubblicazioni e link utili
Pubblicazioni generali
- Lipov EG, Joshi JR, Lipov S, Sanders SE, Siroko MK. Cervical sympathetic blockade in a patient with post-traumatic stress disorder: a case report. Ann Clin Psychiatry. 2008 Oct-Dec;20(4):227-8. doi: 10.1080/10401230802435518. No abstract available.
- Lynch JH, Mulvaney SW, Kim EH, de Leeuw JB, Schroeder MJ, Kane SF. Effect of Stellate Ganglion Block on Specific Symptom Clusters for Treatment of Post-Traumatic Stress Disorder. Mil Med. 2016 Sep;181(9):1135-41. doi: 10.7205/MILMED-D-15-00518.
- Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E. Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mil Med. 2014 Oct;179(10):1133-40. doi: 10.7205/MILMED-D-14-00151.
- Hanling SR, Hickey A, Lesnik I, Hackworth RJ, Stedje-Larsen E, Drastal CA, McLay RN. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Reg Anesth Pain Med. 2016 Jul-Aug;41(4):494-500. doi: 10.1097/AAP.0000000000000402.
- Odosso RJ, Petta L. The Efficacy of the Stellate Ganglion Block as a Treatment Modality for Posttraumatic Stress Disorder Among Active Duty Combat Veterans: A Pilot Program Evaluation. Mil Med. 2021 Jul 1;186(7-8):e796-e803. doi: 10.1093/milmed/usaa246.
- Peterson AL, Blount TH, Foa EB, Brown LA, McLean CP, Mintz J, Schobitz RP, DeBeer BR, Mignogna J, Fina BA, Evans WR, Synett S, Hall-Clark BN, Rentz TO, Schrader C, Yarvis JS, Dondanville KA, Hansen H, Jacoby VM, Lara-Ruiz J, Straud CL, Hale WJ, Shah D, Koch LM, Gerwell KM, Young-McCaughan S, Litz BT, Meyer EC, Blankenship AE, Williamson DE, Roache JD, Javors MA, Sharrieff AM, Niles BL, Keane TM; Consortium to Alleviate PTSD. Massed vs Intensive Outpatient Prolonged Exposure for Combat-Related Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023 Jan 3;6(1):e2249422. doi: 10.1001/jamanetworkopen.2022.49422.
- Foa EB, McLean CP, Zang Y, Rosenfield D, Yadin E, Yarvis JS, Mintz J, Young-McCaughan S, Borah EV, Dondanville KA, Fina BA, Hall-Clark BN, Lichner T, Litz BT, Roache J, Wright EC, Peterson AL; STRONG STAR Consortium. Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial. JAMA. 2018 Jan 23;319(4):354-364. doi: 10.1001/jama.2017.21242.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Disturbi correlati a traumi e fattori di stress
- Disordini mentali
- Disturbi da stress, traumatici
- Disturbi da stress, post-traumatici
- Prodotti chimici organici
- Preparati farmaceutici
- Anilides
- Amides
- Composti di anilina
- Ammine
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Ropivacaina
- Soluzione salina
Altri numeri di identificazione dello studio
- HSC20230087H
- W81XWH2220055 (Altro numero di sovvenzione/finanziamento: Department of Defense)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .